Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

Shelley Wood

May 27, 2021

News Daily News

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

Shelley Wood

September 30, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Los Fibroateromas de Casquete Fino Podrían Explicar los Malos Resultados PCI de los Pacientes Diabéticos

Todd Neale

July 06, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Daily News

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

Michael O'Riordan

March 25, 2016

News Daily News

Un Comunicado Científico de AHA Pone de Manifiesto las Disparidades de Género en el Riesgo CV de Pacientes Diabéticos

L.A. McKeown

December 09, 2015

News Daily News

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

L.A. McKeown

December 09, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

Advertisement

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

LDL Control Remains Poor in CAD Patients: NHANES

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Los Fibroateromas de Casquete Fino Podrían Explicar los Malos Resultados PCI de los Pacientes Diabéticos

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

Un Comunicado Científico de AHA Pone de Manifiesto las Disparidades de Género en el Riesgo CV de Pacientes Diabéticos

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content